Replies to post #485 on Intercept Pharmaceuticals (ICPT)

[osaffer]

PBC was not targeted by Genfit, but FDA has asked to Genfit to launch a study in PBC, why ? Because knows that OCA is not efficient enough

The real market is NASH, and we can say that NASH is almost finished for OCA.

FDA recommends an use of 5 mg for PBC, while OCA seems to be a little bit efficient from 25 mg but ... with some negative effects ...

OCA with 10 mg is not really good

$ICPT Japanese Ph2 data not too hot
Primary endpt p=0.053
No improvement in fibrosis score
Confirm high prutitus AE% pic.twitter.com/Kepcxbf5mx

— Andy Biotech (@AndyBiotech) October 28, 2015